[go: up one dir, main page]

MX2025001965A - Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer - Google Patents

Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer

Info

Publication number
MX2025001965A
MX2025001965A MX2025001965A MX2025001965A MX2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A
Authority
MX
Mexico
Prior art keywords
mta
treatment
cooperative
cancer
prmt5 inhibitors
Prior art date
Application number
MX2025001965A
Other languages
English (en)
Inventor
James Thomas Lynch
Ho Man Chan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2025001965A publication Critical patent/MX2025001965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente memoria descriptiva se refiere a métodos de tratamiento de cánceres con el gen MTAP natural que comprenden administrar un inhibidor de PRMT5 sinérgico con MTA a un paciente que lo necesita.
MX2025001965A 2022-08-15 2025-02-17 Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer MX2025001965A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263397996P 2022-08-15 2022-08-15
PCT/EP2023/072364 WO2024038004A1 (en) 2022-08-15 2023-08-14 Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2025001965A true MX2025001965A (es) 2025-04-02

Family

ID=87748037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001965A MX2025001965A (es) 2022-08-15 2025-02-17 Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer

Country Status (10)

Country Link
EP (1) EP4572760A1 (es)
JP (1) JP2025528186A (es)
KR (1) KR20250048049A (es)
CN (1) CN119730853A (es)
AU (1) AU2023327684A1 (es)
CA (1) CA3263923A1 (es)
IL (1) IL318816A (es)
MX (1) MX2025001965A (es)
TW (1) TW202423435A (es)
WO (1) WO2024038004A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201610709UA (en) 2014-06-25 2017-01-27 Glaxosmithkline Ip Dev Ltd Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
TW202122387A (zh) 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
JP7787819B2 (ja) 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021319201A1 (en) * 2020-07-31 2023-02-16 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
KR20230113339A (ko) 2020-11-24 2023-07-28 암젠 인크 Prmt5 억제제로서의 트리사이클 카르복사미드 유도체
AU2021400942A1 (en) 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors
RU2757957C1 (ru) 2020-12-30 2021-10-25 Александр Григорьевич ВИЛЛЕР Роботизированная система и способ проведения эндоваскулярной хирургической операции
JP2024508235A (ja) 2021-02-04 2024-02-26 アムジエン・インコーポレーテツド 三環－アミド－二環ｐｒｍｔ５阻害剤
US20240208912A1 (en) 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
WO2023278564A1 (en) 2021-07-02 2023-01-05 Mirati Therapeutics, Inc. Aminopyridine-based mta-cooperative prmt5 inhibitors
MX2024003076A (es) 2021-09-13 2024-03-27 Astrazeneca Ab Compuestos espirociclicos.
JP2024542145A (ja) 2021-11-05 2024-11-13 ミラティ セラピューティクス、インコーポレイテッド Ｐｒｍｔ５阻害剤としての２－アミノイミダゾール誘導体
US20240408088A1 (en) 2021-11-30 2024-12-12 Abbisko Therapeutics Co., Ltd. Pyrazole derivative, and preparation method therefor and use thereof in medicine
CN116462676A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116462677A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116178347B (zh) 2022-06-29 2025-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Also Published As

Publication number Publication date
CA3263923A1 (en) 2024-02-22
CN119730853A (zh) 2025-03-28
EP4572760A1 (en) 2025-06-25
IL318816A (en) 2025-04-01
TW202423435A (zh) 2024-06-16
AU2023327684A1 (en) 2025-03-20
WO2024038004A1 (en) 2024-02-22
KR20250048049A (ko) 2025-04-07
JP2025528186A (ja) 2025-08-26

Similar Documents

Publication Publication Date Title
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024009727A (es) Terapias de combinacion.
SA522431915B1 (ar) Prmt5 مثبطات mta تعاونية مع
MX2022009347A (es) Terapia de combinacion para el tratamiento del crecimiento celular anormal.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
PH12022550015A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
MX2009007777A (es) Terapia de combinacion que comprende romidepsina y bortezomib.
MX2025001965A (es) Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2025007373A (es) Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta
MX2023011790A (es) Terapias combinadas para tratar el cancer.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof